What does DSIP cost and what drives its pricing?

DSIP carries no list price anywhere, because no regulator has approved it and no pharmacy stocks it, so every figure in circulation is what a research-supply seller happens to be asking on a given day. The chemistry itself is genuinely cheap, which means the spread between two listings reports on the seller's testing, overhead, and margin far more than on the molecule.

What price range is typically reported for DSIP, and in what units is it sold?

Listings are denominated per vial rather than per dose or per milligram, and that is the first place comparisons quietly break down. A per-milligram figure derived from a ten-vial kit and one derived from a single 5 mg vial are not describing the same purchase, and the gap between them is discounting rather than material.

• Unit of sale: Lyophilized powder priced per vial, most commonly at 2 mg or 5 mg fills.
• Reported figure: Roughly twenty to sixty US dollars per 5 mg vial, a perishable snapshot.
• Volume effect: Multi-vial kits and bulk lots are discounted per unit, collapsing per-milligram comparisons.
• Currency and payment: Quoted in US dollars regardless of supplier location, with some rates tied to payment method.

Does an unusually low price signal a quality or authenticity problem?

A low listing is not evidence of a bad vial, and reading quality out of price alone fails in both directions. The narrower problem is that the specific costs a seller can cut to reach the bottom of the range are the ones that would otherwise protect whoever ends up holding the vial: lot-specific independent testing, purification depth, accurate fill weight, and controlled handling.

What determines the underlying cost of synthesizing a nine-amino-acid peptide?

Peptide cost tracks three things: chain length, sequence difficulty, and the purity a lot has to reach. Batch scale cuts across all three, since fixed setup, column, and analytical costs spread across a larger run, which is why gram-scale synthesis can undercut milligram-scale by an order of magnitude on a per-milligram basis.

1. Chain assembly: Solid-phase peptide synthesis adds one residue at a time, each coupling cycle consuming protected amino acids, activating reagents, and solvent, so cost scales roughly with chain length. At nine residues DSIP sits at the cheap end, with a raw material bill modest next to peptides two or three times its length.
2. Coupling difficulty: Certain motifs aggregate on the resin and force repeated or extended couplings that burn reagent and depress yield. DSIP's glycine- and alanine-rich sequence contains no cysteine, so no disulfide formation or oxidative folding is needed, and no cyclization, N-terminal acetylation, or C-terminal amidation is called for.
3. Purification: Reverse-phase HPLC separates the target chain from deletion and truncation sequences that differ from it only slightly, and pushing a lot from roughly ninety percent to ninety-eight percent or higher means discarding more material and running more column time. This is usually the larger share of the finished cost, with purity and yield trading directly against each other.

Why do quoted prices for the same peptide vary so widely across the market?

Dispersion is wide because almost nothing anchors it. There is no reference price, no regulated margin, no formulary, and no requirement that two identically labeled vials contain the same thing, so sellers price against perceived positioning rather than a shared standard.

How do purity verification and third-party testing affect what a peptide costs?

Analytical work is a real and frequently underappreciated line item, and it is the clearest point at which cost and confidence actually separate. Confirming identity and purity normally runs reverse-phase HPLC to quantify the target chain against impurities and mass spectrometry to check the observed molecular weight against the intended sequence, with amino acid analysis, Karl Fischer water content, and endotoxin or bioburden testing added where the intended use warrants it. A full independent panel run by an outside laboratory can cost more than a single vial of the peptide, which is precisely why it is not universal here.

How does regulatory status shape what DSIP costs and how it is priced?

Regulatory status is the reason DSIP pricing looks nothing like drug pricing. DSIP is not an approved medicine in the United States, the European Union, or other major jurisdictions and has not completed the clinical evaluation approval would require, so nothing in the chain behaves like a medicine's price.

• No approved product: No marketing authorization, manufacturer list price, negotiated payer rate, or reimbursement exists.
• Reagent cost structure: Trial spend, pharmacovigilance, cGMP manufacturing, and distribution compliance are absent, holding absolute figures low.
• Oversight gap: No regulator verifies identity, purity, sterility, dose accuracy, or that contents match the label.
• Enforcement effect: Attention to peptides outside approved channels removes suppliers and moves prices independently of production cost.

What ancillary costs sit alongside the price of the vial itself?

The vial price understates what the material actually costs in use, and the gap is not a rounding error. Reconstitution supplies, separately charged carriage, refrigerated storage of a degrading solution, and any independent verification all sit outside the headline figure, and the last of those can rival the peptide it is meant to confirm.

1. Carriage and border exposure: Shipping is charged separately and can be substantial where tracked or expedited international carriage is involved, and cross-border orders may attract customs duties, brokerage fees, or seizure risk that functions as a cost even when it never appears on an invoice.
2. Reconstitution: Lyophilized powder arrives dry and has to be taken into solution before it can be handled, which brings in bacteriostatic or sterile water, transfer and filtration supplies, and suitable containers, none of them included in the listed figure.
3. Storage and shelf life: Dry powder is comparatively stable, but reconstituted peptide degrades and requires refrigeration, so the effective cost per usable milligram climbs whenever a reconstituted vial expires before it is consumed.
4. Independent verification: Testing a received vial rather than trusting a supplied certificate can rival or exceed the price of the peptide it is meant to confirm.